CytoVac A/S   Report issue

For profit Phase 2
Founded: Horsholm Denmark (2008)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2009
NCT00891345
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

CytoVac A/S | CytoVac A/S (Sponsor)

Active Ingredients

Drugs in Phase 2 Trials (2)

alecsat (7 trials)

temozolomide (temodar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Pancreatic Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 2